BACITRACIN ZINC, NEOMYCIN, POLYMYXIN B

N/A

Manufactured by H E B

2,903 FDA adverse event reports analyzed

Last updated: 2026-04-15

About BACITRACIN ZINC, NEOMYCIN, POLYMYXIN B

BACITRACIN ZINC, NEOMYCIN, POLYMYXIN B is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by H E B. The most commonly reported adverse reactions for BACITRACIN ZINC, NEOMYCIN, POLYMYXIN B include DRUG INEFFECTIVE, DIARRHOEA, DYSPNOEA, NAUSEA, DIZZINESS. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for BACITRACIN ZINC, NEOMYCIN, POLYMYXIN B.

Top Adverse Reactions

DRUG INEFFECTIVE131 reports
DIARRHOEA84 reports
DYSPNOEA84 reports
NAUSEA72 reports
DIZZINESS70 reports
RASH69 reports
HEADACHE64 reports
MALAISE64 reports
PNEUMONIA64 reports
FATIGUE62 reports
ERYTHEMA60 reports
COUGH59 reports
VOMITING56 reports
PYREXIA50 reports
URINARY TRACT INFECTION45 reports
PAIN42 reports
ASTHENIA41 reports
WEIGHT DECREASED40 reports
PRODUCT QUALITY ISSUE38 reports
FEELING ABNORMAL36 reports
OFF LABEL USE36 reports
PRURITUS36 reports
SINUSITIS36 reports
TREMOR36 reports
BRONCHITIS35 reports
INSOMNIA34 reports
FALL33 reports
ACNE32 reports
DRUG INTERACTION32 reports
ARTHRALGIA31 reports
UNWANTED AWARENESS DURING ANAESTHESIA31 reports
ABDOMINAL PAIN UPPER30 reports
DRUG HYPERSENSITIVITY30 reports
HYPERTENSION29 reports
INFECTION29 reports
DECREASED APPETITE28 reports
NASOPHARYNGITIS28 reports
NEUROPATHY PERIPHERAL28 reports
ABDOMINAL PAIN27 reports
CONFUSIONAL STATE25 reports
HYPERSENSITIVITY25 reports
SOMNOLENCE25 reports
CONDITION AGGRAVATED24 reports
DRUG DOSE OMISSION24 reports
DRY SKIN24 reports
OVERDOSE24 reports
BLOOD GLUCOSE INCREASED23 reports
DEATH23 reports
ANXIETY22 reports
CONSTIPATION22 reports
DEPRESSION22 reports
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION22 reports
BACK PAIN21 reports
MYALGIA21 reports
SEPSIS20 reports
DRUG EXPOSURE DURING PREGNANCY19 reports
DYSPHAGIA19 reports
FLUSHING19 reports
HYPOTENSION19 reports
PARAESTHESIA19 reports
CHEST PAIN18 reports
CHILLS18 reports
DEHYDRATION18 reports
HYPERHIDROSIS18 reports
MEMORY IMPAIRMENT18 reports
PAIN IN EXTREMITY18 reports
PLATELET COUNT DECREASED18 reports
ABDOMINAL DISCOMFORT17 reports
ASTHMA17 reports
HYPOXIA17 reports
OEDEMA PERIPHERAL17 reports
DRUG ADMINISTRATION ERROR16 reports
DYSGEUSIA16 reports
HEART RATE INCREASED16 reports
LOSS OF CONSCIOUSNESS16 reports
RESPIRATORY FAILURE16 reports
STOMATITIS16 reports
SWELLING FACE16 reports
GASTROOESOPHAGEAL REFLUX DISEASE15 reports
INCORRECT DRUG ADMINISTRATION DURATION15 reports
MUSCLE SPASMS15 reports
NERVOUSNESS15 reports
OROPHARYNGEAL PAIN15 reports
UPPER RESPIRATORY TRACT INFECTION15 reports
WHEEZING15 reports
CHEST DISCOMFORT14 reports
GAIT DISTURBANCE14 reports
HYPOAESTHESIA14 reports
PHARMACEUTICAL PRODUCT COMPLAINT14 reports
SKIN IRRITATION14 reports
CONVULSION13 reports
CRYING13 reports
HAEMORRHAGE13 reports
ILL DEFINED DISORDER13 reports
INFLUENZA13 reports
MUSCULAR WEAKNESS13 reports
SKIN BURNING SENSATION13 reports
VISION BLURRED13 reports
BLOOD PRESSURE INCREASED12 reports
DRY MOUTH12 reports

Report Outcomes

Out of 1,588 classified reports for BACITRACIN ZINC, NEOMYCIN, POLYMYXIN B:

Serious 52.8%Non-Serious 47.2%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female905 (64.0%)
Male497 (35.1%)
Unknown13 (0.9%)

Reports by Age

Age 6430 reports
Age 5523 reports
Age 5923 reports
Age 5721 reports
Age 7921 reports
Age 4619 reports
Age 5819 reports
Age 6319 reports
Age 7119 reports
Age 7218 reports
Age 6017 reports
Age 7417 reports
Age 7016 reports
Age 7616 reports
Age 1515 reports
Age 4915 reports
Age 5015 reports
Age 5215 reports
Age 6115 reports
Age 6215 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with BACITRACIN ZINC, NEOMYCIN, POLYMYXIN B?

This profile reflects 2,903 FDA FAERS reports that mention BACITRACIN ZINC, NEOMYCIN, POLYMYXIN B. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for BACITRACIN ZINC, NEOMYCIN, POLYMYXIN B?

Frequently reported terms in FAERS include DRUG INEFFECTIVE, DIARRHOEA, DYSPNOEA, NAUSEA, DIZZINESS, RASH. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures BACITRACIN ZINC, NEOMYCIN, POLYMYXIN B?

Labeling and FAERS entries often list H E B in connection with BACITRACIN ZINC, NEOMYCIN, POLYMYXIN B. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.